Tag: fees

Trading to Commence Under Symbol “BTCT”

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”) (NYSE:BLK) today announced updates to the investment risk ratings of certain iShares exchange-traded funds (“iShares ETFs”), a reduction to the annual management fees of certain iShares ETFs, and the commencement of securities lending transactions of certain iShares ETFs, as further described below.

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- GraniteShares has announced it will execute a forward share split for the GraniteShares 2x Long PLTR (the “Fund”). The total market value of the shares outstanding will not be affected as a result of these splits.

SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- With the price of Bitcoin fluctuating around $100,000, many analysts predict that the cryptocurrency market will remain in a state of high volatility for a long time. Holding spot positions may struggle to generate short-term profits in such conditions. As a result, 100x leverage futures trading has become the preferred tool for seasoned investors looking to maximize potential gains in this volatile market. BexBack Exchange is ramping up its efforts to offer traders unmatched promotional packages. The platform now features a 100% deposit bonus, a $50 welcome bonus for new users, and 100x leverage on cryptocurrency trading, providing exceptional opportunities for investors.

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Canadian Life Companies Split Corp. (“the Company”) is pleased to announce it has completed the overnight offering of Preferred Shares and Class A Shares of the Company. Total gross proceeds of the offering were $40.0 million, bringing the Company’s net assets to approximately $217.9 million.

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 shares of its common stock (or common stock equivalents in lieu thereof) together with Series C warrants to purchase up to 20,000,000 shares of common stock (the "Series C Warrants") and Series D warrants to purchase up to 20,000,000 shares of common stock (the "Series D Warrants"), at a combined offering price of $0.50 per share and accompanying warrants, for aggregate gross proceeds of approximately $10 million before deducting placement agent fees and other offering expenses.